Cemiplimab significantly improves DFS in patients with high-risk CSCC post-surgery, reducing recurrence or death risk by 68% compared with placebo. The C-POST trial marks the first immunotherapy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results